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Residual risk of transmission ofHIV through blood
transfusion in South Africa'
F. SITAS, A. F. FLEMING, J. MORRIS
Abstract Despite the ongoing review of donor recruitInent
criteria by local blood transfusion services and the
developlIlent of highly sensitive and specific test-
ing for the presence of antibodies to mv in blood
and blood products, there relIlains a residue of
mv in donated blood. This is because of donors
who are in the 'window period' between acquisi-
tion ofmv and seroconversion, hum.an errors and
lim.its to the' sensitivity and specificity of current
tests. Data available frOIIl a national survey ofmv
seroprevalence in South African blood donors
allowed for the estim.ation of the num.ber of units
screened negative but likely to be infected with
HIV. AssulIling window periods of 4,8 and 14
weeks, a test sensitivity of 99,9%, a specificity of
98,5% and a hum.an error rate of 0,1%, the likely
rate of HIV-infected blood in the South African
blood transfusion supply ranges frOIIl 1,1 to 3,9/
100 000 units, with a likely estim.ate of 2,21100000
units. In the current South African blood trans-
fusionsetting, between 8,1 and 28,2 units of blood
per annum. will be mv-positive with a likely esti-
lIlate of 15,9 units. This corresponds to an odds
ratio of between 1:90 909 and 1:25 641 units in-
fected with mv. These data are cOlIlparable with
the risk in developed countries. The expected
increase in the incidence and prevalence of mv
infection in all adult South African populations
necessitates additional lIleasures to ensure a blood
supply which is as safe as possible. SOlIle of these
lIleasures have already been taken by local blood
transfusion services.
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I n countries with well-developed policies on bloodtransfusion, including South Africa, the risk of trans-mission of HIV to recipients is now nearing the
minimum that is technically possible. This has been
achieved since 1985 through, for example, the exclusion
of blood donors whose behaviour may put them at risk
of HIV infection, the application of highly sensitive and
specific tests to screen all donated blood for antibodies
to HIV, and virus inactivation of blood products. There
remains, however, a residue of infections because of
infected blood donors who are in the 'window period'
between acquisition of HIV and seroconversion, human
errors and the limits to the sensitivity and specificity of
the antibody test. The risk of seroconversion after trans-
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fusion of HIV-infected blood has been shown to be
44/46 (96%) in Zaire.' Experience in both the USA and
Zambia has shown that AIDS may develop rapidly after
infection by transfusion, related possibly to the size of
viral inoculation. 2,3
There have been four distinct approaches to calculat-
ing the residual risk of transmission of HIV by blood
transfusion. An epidemiological approach assumed that
all HIV infections detected serologically in first-time
donors were pre-existing or prevalent infections, and
that all infections detected in repeat blood donors were
new or incident infections. During 1986 - 1987,0,012%
of repeat blood donors and 0,041 % of first-time blood
donors in the USA had HIV antibody. Ward et al. 4
assumed that the median length of the window period
was 8 weeks and calculated the rate of HIV infections
by HIV-antibody-negative blood donations to be
2,6/100 000. The estimated rate of HIV-infected units
entering the supply from American Red Cross donations
in 1987 was 0,65/1 00 000, and the rate was falling by.
more than 30% per year. 5
A second approach has been to measure the inci-
dence of HIV in defined populations of patients who
have high requirements for blood transfusions. Two
seroconversions were observed after 80 630 units of
blood or blood components were transfused to patients
undergoing cardiac surgery in Baltimore and Houston;
t4is gave an estimated risk of HIV-infected units of
2,5/100 000 with an upper 95% confidence limit of
7,8/100 000 unitsY The observed incidence of HIV
since the introduction of antibody screening in a trans-
fusion-dependent population of Italians with thalas-
saemia major showed that the residual risk of HIV-
infected units was approximately 2/100 000 units. 8
A third approach, a retrospective 'lookback' method,
consisted of HIV antibody testing of living recipients of
HIV-seronegative units donated by persons who later
tested HIV seropositive at the time of a subsequent
donation. In Los Angeles it was estimated that the re-
sidual risk of HIV-infected units was most probably
1,47/100 000, and was within the range 0,99 - 1,98/
100 000 units;" these calculations were based on obser-
vations from repeat donors, and may be underestimates
if the incidence of infections is higher in first-time than
in repeat donors.
A fourth approach measured the prevalence of HIV
in 71 800 HIV-seronegative donations through the
detection of virus by culture and polymerase chain re-
action. In California, the probability of an HIV-sero-
negative donor being infected was estimated to be
1,6/100 000 units, with an upper 95% confidence limit
of 9,4/1 00 000 units. to
All four approaches have yielded results which are
remarkably consistent and suggest that in north America
and western Europe the residual risk of HIV-infected
units is most probably in the range of 0,65 - 2,6/100 000
units.
The risks are significantly greater when blood donors
test anti-HIV-negative in tropical Africa. In the Ivory
Coast in 1991 the overall prevalence of HIV was 11,0%
in first-time blood donors and 2,1 % in repeat blood
donors. The incidence of HIV infection in first-time and
repeat blood donors was assumed to be the same, 1,2%
per year. However the authors unnecessarily multiplied
the risk of iilfection in the repeat donors by the fre-
quency of donations. This is incorrect and overestimates
the residual risk of RN infection of blood products in
the repeat donor population. The risk of a unit being
infected with HIV is unrelated to the frequency of dona-
tions (see 'Methods'). After the necessary correction, we
calculate the risk of RN infection from blood transfu-
sion in the Ivory Coast to be 2,4 - 4,411 000, compared
with the authors' calculated 5,4 - 10,1/1 000 units."
Recent data available from a national survev of RN
seroprevalence in South African blood donors '2 allowed
for the estimation of the overall number of units
screened negative bur likely to be infected with RN.
Methods
The following need to be taken into account in the esti-
mation of blood units likely to be infected with RIV
despite screening:
1. The accuracy of the screening test. This
entails the false-negative value of a test (Fl'\T), defined as
the proportion of blood samples falsely showing a nega-
tive result, but which are, in fact, RN infected, or 1
minus the predictive negative value of a test. The FN is
dependent on·the sensitivity (S, assumed to be 99,9%),
the specificity of the test (Q, assumed to be 98,5%) and





(1-S) x P + (1-P) x Q
Number of units per 100 000 missed by the test =
FNx 100000.
Given the current 0,2% approximate prevalence rate
of RN infection in the South African blood transfusion
setting, the number of false negatives would be 0,2/
100 000 units and is therefore ignored. These sensitivi-
ties and specificities are, however, calculated against a
Western blot assessment which may fail to identify the
presence of some recent RN illfections.
2. Window period (WP). The time between infec-
tion with RN and a positive antibody test is the most
imporrant cause for concern in blood transfusion set-
tings. Estimates of the window period range from 4 to
14 weeks with a most likely period of 8 weeks.4-0
3. Hwnan error (RE). This is unlikely given the
competence of blood transfusion technical staff. Never-
theless, an error rate of 0,1 % (or 100/100 000) was
assumed as a worst-case scenario, as was done else-
where.'
4. Incidence and prevalence asswnptions. In
first-time donors the given prevalence of RN infection
was 0,198% (198,065/100 ODD)." To calculate the inci-
dence of infection (1), data are required on the duration
(D) of RN infection (I =P/D). In the absence of such
information for South Africa and for the sake of simplic-
ity the duration was assumed to be 5 years.'
For first-time donors, r..1}e formula for calculating the
proportion of units likely to be positive bur undetected
by screening is I x WP/52 + (P x HE).
For repeat donors both the incidence rate and the
window period have to be adjusted for the interval
between donations. Therefore if F is the frequency of
donations per year, the formula becomes: (Annual inci-
dence ratelF) x (WP/52) x F + (HE x P). This reduces
to: I x WP/52 + (HE x P).
In other words, unlike the assumptions of Savarit et
al." the risk of units being infected with RN is un-
affected by the number of donations per year. In the
repeat donor population the prevalence of RN infection
is calculated by multiplying the annual incidence rate by
the period between screens (Ds). In the repeat donors
the measure of prevalence (i.e. the overall number of
positive results at one time) becomes equivalent to the
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incidence rate (the number of new occurrences on each
interval between donations).'
Results
For firsl-lime donors, assuming a window period of
4 - 14 weeks, with a most likely period of 8 weeks, the
risk of undetected units infected with RIV ranges
between:
Minimum = 39,6 x (4/52) + (198,065 x 0,001)
3,2/100000 units;
Likely = 39,6 x (8/52) + (198,065 x 0,001)
6,2/100000 units;
Maximum = 39,6 x (14/52) + (198,065 x 0,001) =
10,9/100 000 units.
The incidence in South African repeal donors over a
6-month period ranged from 0,0006% to 0,006%," the
midpoint of which is 6,6/100 000 per annum. The aver-
age frequency of donations per year was 2,7 (R. L.
Crookes - personal communication). This translates as
a donation every 12/2,7 = 4,44 months (Ds = 0,37
years). The incidence of RN per screening interval in
repeat donors is therefore 6,6 x (4,44/12) = 2,46/
100 000 (per 4,44 months). The prevalence of RN
infected units in repeat donors is I x D s =6,6 x 0,37 =
2,46/1 00 000. The risk of units being infected \\~th RN
bur undetected by screening given window periods of 4,
8 and 14 weeks would then be:
Minimum = 6,6 x (4/52) + (2,46 x 0,001)
0,5/100000 units;
Likely = 6,6 x (8/52) + (2,46 x 0,001)
1,0/1 00 000 units;
Maximum = 6,6 x (14/52) + (2,46 x 0,001)
1,8/100000 units.
Roughly 810 000 donations are made each year,
185 000 of which are from first-time donors and
625 000 from repeat donors. 12 Assuming 90% are used
to make red blood cell, plasma and other non-heat-
treated blood components, 562 500 units from repeat
donors and 166 500 units from first-time donors are
potentially at risk.
The total number of undetected RN-infected units
per annum for first-time donors therefore ranges from a
minimum = 166 500 x (3,2/100 000) = 5,3 units, to a
maximum = 166 500 x (10,9/100 000) = 18,1 units,
with the most likely estimate 166500 x (6,2/100 000) =
10,3 units.
For repeat donors the number ranges from a mini-
mum =562 500 x (0,5/100 000) =2,8 units, to a maxi-
mum =(562 500 x (1,8/100 000) = 10,1 units, with the
most likely estimate 562 500 x (1/100 000) =5,6 units.
In any 1 year, therefore, between 8,1 (5,3 + 2,8) and
28,2 (18,1 + 10,1) units of blood will be RN-positive
and undetected by screening with 15,9 units the most
likely estimate. This translates as an odds ratio of
1:90 909 to 1:25 641 units being infected with RN
(likely = 1:45 849). In other words, the risk of RN
infection per 100 000 units ranges from 1,1 to 3,9, with
a most likely estimate of2,2 units.
In the USA, an average of 5,4 units are required per
transfusion! By contrast, in the South African Blood
Transfusion Services (SABTS), 2,3 units are required
per case (A. Du P. Reyns - personal communication).
Assuming that the SABTS data of 2,3 units per case
reflect a nation-wide average, this would translate in
South Africa as an odds of 1:39 526 to 1: 11 148 persons
accidentally acquiring RN-infected blood from blood
transfusion (likely: 1: 19 934), or a risk of 2,53 - 9,0/
100 000 persons. These risks decrease to a more
favourable level if due adjustments are made for the
morrality rates of the conditions requiring blood transfu-





The estimated risk of residual HIV infectivity of trans-
fused blood in South Africa is in the same range as that
estimated in the USA and ltaly.4-IO The slightly higher
risk in South Africa when compared with some of the
data from the USA is a reflection of the higher preva-
lence in first-time donors and higher incidence of infec-
tion in repeat donors.
In South Africa, between 1986 and 1991,73% of
blood donors were white and 15% black. 12 The sero-
prevalence of the adult black population is currently
doubling approximately every year and it is predicted
that by the year 2005 between 18% and 24% of the
adult population will be infected with HIV_1. 14-l6 At the
present stage of the pandemic, heterosexual transmis-
sion of HIV is affecting the black population worst, but
it is foreseen that there will be a rising incidence and
prevalence in the whole heterosexual community of
South Africa. The inevitable increase in seroprevalence
of HIV will lead to an escalating danger of HIV being
transmitted by the transfusion of blood which tests anti-
body negative. Black donors happen to have the highest
prevalence of HIV at this stage of the epidemic, but in
all other respects the full participation of the black pop-
ulation in the voluntary blood donation scheme is both
desirable and likely to happen, especially after political
enfranchisement. A closer coincidence between the
donor population and the recipients of blood results in
(z) the more economical use of blood, e.g. there would
be no excess of group A blood drawn from white donors
and not utilised; (iz) a greater ease in finding compatible
blood, e.g. a sufficient supply of group B; and (iiz) a
reduced risk of allo-immunisation.
It is important to emphasise that high- or low-risk
behaviour is not restricted to one population group and
exclusion of blood donors on the basis of their popula-
tion group alone would be unacceptable. Some blood
transfusion services are pursuing a policy of recruiting
lower-risk black blood donors who, for example, include
men between 16 and 20 years and people of both sexes
over the age of 45 years. I7 Important risk factors asso-
ciated with the transmission of HIV include multiple sex
partners, lower rates of condom use and the presence of
sexually transmitted diseases.
It should be a priority continually to revise national
policy to limit the transmission of HIV through blood
transfusion. Strategies which could be considered
include: (z) an intensive campaign of education among
potential blood donors as to the importance of hetero-
sexual transmission of HIV and the undesirability of
donors who have multiple or unknown sex partners; (iz)
pre-donation education should be targeted at teenagers,
because the recruitment of young adults as first-time
donors is essential for the maintenance of the blood sup-
ply, and they are the age group most likely to be'in the
window period; (iiz) the expansion of the pool of regular
donors who repeatedly test HIV negative; (iv) the recog-
nition of groups with a high frequency of HIV risk
behaviour which, in the African context, include sex
workers, prisoners, inhabitants of single-sex hostels, the
uniformed services and long-distance lorry drivers;lS.l9
(v) the use of blood from first-time blood donors for the
preparation of virus-inactivated blood components and
laboratory reagents only; (vz) a constant search for and
the application of new tests of greater sensitivity, capable
of detecting HN during the window period; (viz) the
preparation, dissemination and application of national
guidelines on the appropriate use of blood and blood
products, based on those of the Global Blood Safety
Initiative of the Global 'Programme on AIDS of the
World Health Organisation;'" and (vizi) primary health
care interventions aimed at reducing the frequency of
the need to transfuse through, for example, the preven-
tion of anaemia in childhood and pregnancy and the
anticipation of obstetric haemorrhage and other compli-
cations. IS,21
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